Abstract
The mitochondria-bound adapter MAVS participates in IFN induction by recruitment of downstream partners such as members of the TRAF family, leading to activation of NF-kappaB, and the IRF3 pathways. A yeast two-hybrid search for MAVS-interacting proteins yielded the Polo-box domain (PBD) of the mitotic Polo-like kinase PLK1. We showed that PBD associates with two different domains of MAVS in both dependent and independent phosphorylation events. The phosphodependent association requires the phosphopeptide binding ability of PBD. It takes place downstream of the proline-rich domain of MAVS, within an STP motif, characteristic of the binding of PLK1 to its targets, where the central Thr234 residue is phosphorylated. Its phosphoindependent association takes place at the C terminus of MAVS. PLK1 strongly inhibits the ability of MAVS to activate the IRF3 and NF-kappaB pathways and to induce IFN. Reciprocally, depletion of PLK1 can increase IFN induction in response to RIG-I/SeV or RIG-I/poly(I)-poly(C) treatments. This inhibition is dependent on the phosphoindependent association of PBD at the C terminus of MAVS where it disrupts the association of MAVS with its downstream partner TRAF3. IFN induction was strongly inhibited in cells arrested in G2/M by nocodazole, which provokes increased expression of endogenous PLK1. Interestingly, depletion of PLK1 from these nocodazole-treated cells could restore, at least partially, IFN induction. Altogether, these data demonstrate a new function for PLK1 as a regulator of IFN induction and provide the basis for the development of inhibitors preventing the PLK1/MAVS association to sustain innate immunity.
Highlights
Initial spread of these infections and involves the production of inflammatory cytokines and type I interferons (IFN␣/)6 [1]
The interaction between MAVS and the PLK1-Polo-box domain (PBD) was confirmed in human cells using a mammalian two-hybrid assay in which the PLK1-PBD sequence was fused in-frame with the DNAbinding domain of Gal4, while the MAVS sequence was fused to the transactivator VP16
We showed that MAVS behaves as a target for PLK1 based on the fact that full association of MAVS with PLK1 requires the phosphopeptide binding motif of PLK1 (Fig. 2) and based on in vivo phosphorylation events (Fig. 3)
Summary
Initial spread of these infections and involves the production of inflammatory cytokines and type I interferons (IFN␣/)6 [1]. To Expression of PLK1, PLK1-PBD, and MAVS in total cell extracts was controlled with anti-FLAG or anti-Myc antibodies. The MAVS N-terminal domain associates only to the PLK1-PBD construct with phosphopeptide binding ability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have